Brentuximab vedotin for refractory anaplastic lymphoma kinase-negative anaplastic large cell lymphoma in leukemic phase with RUNX3 overexpression

Anaplastic lymphoma kinase (ALK)- negative anaplastic large cell lymphoma (ALCL) is an aggressive CD30-positive non- Hodgkin lymphoma. ALK-ALCL rarely manifests with extensive bone marrow and peripheral blood involvement (known as “leukemic phase”). A 54-year-old woman was diagnosed with ALK-ALCL in...

Descripción completa

Detalles Bibliográficos
Autores principales: Yamashita, Yusuke, Hori, Yoshikazu, Kosako, Hideki, Oiwa, Takehiro, Warigaya, Kenji, Mushino, Toshiki, Murata, Shogo, Fujimoto, Masakazu, Nishikawa, Akinori, Murata, Shin-ichi, Sonoki, Takashi, Tamura, Shinobu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: PAGEPress Publications, Pavia, Italy 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7256628/
https://www.ncbi.nlm.nih.gov/pubmed/32499905
http://dx.doi.org/10.4081/hr.2020.8368

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7256628/
https://www.ncbi.nlm.nih.gov/pubmed/32499905
http://dx.doi.org/10.4081/hr.2020.8368

Ejemplares similares